Drug delivery technologies have enabled the development of many pharmaceutical products that improve patient health by enhancing the delivery of a therapeutic to its target site, minimizing off-target accumulation and facilitating patient compliance. As
of Alnylam’s product candidates or its marketed products; obtaining, maintaining and protecting intellectual property; Alnylam’s ability to manage its growth and operating expenses through disciplined investment in operations and its ability to achieve a self-sustainable financial profile in the future ...
FINRA and Alnylam Pharmaceuticals share their experiences in taking the necessary risks to apply AI to their business. Novartis Discover how Novartis transformed their campaigns with Dataiku for more personalized experiences. Air Canada and Royal Bank of Canada ...
been employees of Alnylam Pharmaceuticals during the writing of the manuscript and report ownership of equity in Alnylam Pharmaceuticals: V.J. is chief technology officer; A.V. is chief innovation officer; K.F. is chief scientific officer; and M.A.M. is senior vice-president, head of ...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) today announced the positive outcome of the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting to discuss the supplemental New Drug ...
2. Common nanoparticles used in disease treatment and diagnostics 3. Advancements in the clinical application of cancer nanomedicines 4. Challenges and countermeasures in translating cancer nanomedicine from the bench to the bedside 5. Case studies and practical applications 6. Future opportunities in can...
Drug delivery technologies have enabled the development of many pharmaceutical products that improve patient health by enhancing the delivery of a therapeutic to its target site, minimizing off-target accumulation and facilitating patient compliance. As
The armamentarium for the treatment of dyslipidemia today comprises six different modes of action with overall around 24 different drugs. The treatment of lipid disorders was revolutionized with the introduction of statins which have become the most impo
Levin noted, too, how many of industry’s most prolific biotechs, from Genentech to Regeneron to Alnylam Pharmaceuticals, weren’t immune to broader economic struggles. “People forget companies that look successful today were real dogs at some stage, because of the market,” he said. ...
The HexakisaminoC60 fullerene was an efficient siRNA transfection agent, and decreased the GFP fluorescence signal significantly in the DU145 cells. Surprisingly, the glycofullerene JK39 was inactive in the transfection experiments, probably due to its high zeta potential and the formation of an ...